Test Price
2,800 AED✅ Home Collection Available
DNAJC19 Gene Dilated Cardiomyopathy with Ataxia NGS Genetic Test in Dubai
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% clinical sensitivity via ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) accredited next-generation sequencing processing.
- Turnaround Time: 10–14 working days from sample receipt to final clinical report.
- Price: 2,800 AED all-inclusive of DHA-regulated laboratory analysis and clinical interpretation.
- Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: DHA-licensed Consultant Medical Genetics telephonic post-test counselling included.
- Insurance: Direct billing verification available via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The DNAJC19 Gene Dilated Cardiomyopathy with Ataxia NGS Test screens the entire coding region and splice-site boundaries of the DNAJC19 gene using high-fidelity Next-Generation Sequencing. This analysis identifies pathogenic and likely pathogenic variants associated with 3-methylglutaconic aciduria type V, a mitochondrial disorder characterized by infantile-onset dilated cardiomyopathy, progressive cerebellar ataxia, growth failure, and elevated 3-methylglutaconic acid in urine. Early molecular diagnosis through this test enables targeted cardiac surveillance, metabolic management, and informed family planning.
| Feature | DNAJC19 NGS Test (DNA Labs UAE) | Alternative Sanger Sequencing |
|---|---|---|
| Technology | Full gene NGS (Paired-End Reads) | Single-gene Sanger sequencing |
| Coverage | Complete coding region + 10 bp flanking splice sites | Limited to known hotspot mutations |
| Turnaround Time | 10–14 Working Days | 4–6 Weeks |
| Clinical Sensitivity | >99% for DNAJC19 variants | ~80% (misses novel/private mutations) |
| Regulatory Compliance | DHA-licensed, ISO 9001:2015, UAE PDPL compliant | Non-accredited international laboratory |
| Price (AED) | 2,800 AED | 3,200 – 4,500 AED |
Physician Insight & Safety Protocols
“A positive DNAJC19 result in the context of suspected 3-methylglutaconic aciduria type V requires careful correlation with clinical phenotyping, cardiac imaging, and metabolic markers. Variant interpretation must be integrated with family history to guide cascade screening and risk stratification. This test should always be ordered alongside formal genetic counselling to ensure informed clinical decision-making.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue, alter, or adjust prescribed cardiac medications (including beta-blockers, ACE inhibitors, or diuretics) without explicit consultation with your treating cardiologist. Sudden medication changes in patients with dilated cardiomyopathy can precipitate acute heart failure or arrhythmic events.
Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Sample Collection:
- Acute febrile illness or active systemic infection
- Sample not collected in a DHA-approved standardized collection kit
- Inability to obtain valid informed consent for genetic testing
- Blood transfusion received within the last 2 weeks
- Known bone marrow transplant recipient (chimerism interferes)
ER Red Flags (Seek Immediate Medical Attention):
- New-onset or worsening severe chest pain
- Syncope (fainting) or sudden collapse
- Palpitations accompanied by lightheadedness
- Severe shortness of breath at rest or minimal exertion
- Sudden swelling in legs or abdomen
Patient FAQ & Clinical Guidance
1. What is the DNAJC19 gene test and how does it help?
This test uses advanced next-generation sequencing to detect disease-causing variants in the DNAJC19 gene. It helps confirm a diagnosis of dilated cardiomyopathy with cerebellar ataxia, enabling early institution of cardiac surveillance, metabolic management, and genetic counselling for family members.
2. Who should consider undergoing this genetic analysis?
Individuals presenting with unexplained infantile or childhood-onset dilated cardiomyopathy, progressive ataxia, growth delay, elevated 3-methylglutaconic acid, or a family history suggestive of 3-methylglutaconic aciduria type V should pursue testing after formal pre-test genetic counselling.
3. How long does it take and what do results mean for my health?
Results are reported within 10 to 14 working days. A pathogenic result confirms the genetic basis of the condition, guiding proactive cardiac and neurological management. A negative result significantly reduces the likelihood of DNAJC19-related disease but does not exclude all genetic causes of cardiomyopathy and ataxia.
4. How is the sample collected and can I do it from home?
The test requires a standard peripheral whole blood sample. We offer VIP Mobile Phlebotomy services with temperature-controlled cold-chain transport directly to our DHA-licensed laboratory in Dubai Healthcare City, ensuring sample integrity and rapid processing.
UAE Regulatory & Data Privacy Adherence
This genetic test is performed under the regulatory oversight of the Dubai Health Authority (DHA Facility License Number: 1143) by DNA Labs UAE. All patient data, genetic information, and clinical records are processed and stored in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety protocols and informed consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Patient confidentiality and data security are enforced at every stage of the diagnostic pathway.
Clinical & Logistical Metadata
| Test Name | DNAJC19 Gene Dilated Cardiomyopathy with Ataxia NGS Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 10–14 Working Days |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA tube) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coverage |
| ICD-10-CM Code | I42.0 (Dilated cardiomyopathy), G11.1 (Early-onset cerebellar ataxia) |
| LOINC Code | 94224-6 (Cardiomyopathy comprehensive gene panel) |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians